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aptoglobin:  an emerging  candidate  for
henotypic modulation  of sickle  cell  anemia?agnun Nueldo Nunes dos Santos
zilniversidade Estadual de Campinas (UNICAMP), Campinas, SP, Bra
ickle cell anemia (SCA) is characterized by a single homozy-
ous mutation (A→T)  in the sixth codon of the -globin gene
hat results in hemoglobin S (Hb S), in which a glutamic
cid residue is substituted by valine in the sixth position
f the -globin chain (HBB; glu(E)6val(A); GAG-GTG; rs334).1
his change leads to a wide variety of symptoms, including
hronic intravascular hemolysis, increased cell-free plasma
emoglobin (Hb) and heme levels and vascular alterations.2
CA has been characterized as a chronic inﬂammatory state
ith abnormal endothelial activation as a result of various
ssociated factors. The mechanisms that induce the pro-
uction of inﬂammatory mediators and the effects of these
olecules on the inﬂammatory response are little understood
n this disease.3
Sickled red blood cells are stiff and therefore have a predis-
osition to hemolysis; one third of the cells are destroyed in
he intravascular space leading to increased cell-free plasma
b and heme levels.4 The pathophysiological effects associ-
ted with free Hb/heme are acute hemodynamic instability
nd acute or chronic vascular injury.5 The toxicity and inﬂam-
atory nature of free Hb are a result of the greater nitric oxide
onsumption it promotes and the consequent accumulation
f hydroxyl radicals and reactive oxygen species in the blood
essels. The organism’s ﬁrst defense mechanism against the
armful effects of free Hb involves haptoglobin (Hp), whose
rimary function is to bind to free Hb in the plasma, thereby
reventing the excretion of iron by the kidneys and protec-
6,7ing blood vessels from its oxidative effects. In addition to
eing an antioxidant, Hp is a positive acute-phase glycopro-
ein present in plasma with immunomodulatory properties.6,7
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eserved.It is mainly synthesized in hepatocytes whose production
is induced by the secretion of interleukin (IL)-6, IL-1 and
tumor necrosis factor-alpha (TNF-).8 Hp has a strong afﬁn-
ity for Hb, forming a highly stable complex by binding to Hb
dimers (Figure 1). This Hb–Hp complex binds to CD163 recep-
tors expressed on the surface of macrophages in the spleen,
liver, bone marrow and kidneys, and is removed from the blood
vessels.9 However, when this system for eliminating free Hb
is overloaded because of intravascular hemolysis, as in SCA,
free Hb/heme trigger adverse clinical effects, such as nitric
oxide depletion, oxidative stress, endothelial dysfunction and
exposure of the kidneys to the iron in Hb/heme.4
In humans, the HP gene, on the long arm of chromo-
some 16 (16q22), is polymorphic. There are two  principal
codominant alleles (HP1 and HP2) resulting in three main
genotypes/phenotypes (Hp1-1, Hp2-1 and Hp2-2), which have
distinct biochemical and biophysical properties and have been
correlated to susceptibility to and clinical evolution of vari-
ous diseases.6,7,10 The HP2 allele is a partially duplicated gene
derived from a rare unequal crossover between the HP1 alleles.
Because of its large size, the Hp2-2 protein has been shown to
be less efﬁcient at clearing Hb from the plasma than the Hp1-1
protein. Thus, subjects with Hp2-2 are more  prone to oxidative
stress.6,11,12
Recently, several studies have investigated the possibility
of the therapeutic use of Hp in hemolytic anemias.4,5,13 It was
demonstrated in guinea pigs that Hp is efﬁcient at preventing;37(5):329–35.
edical Sciences, Universidade Estadual de Campinas (UNICAMP),
.com
arterial hypertension and kidney damage induced by plasma
free Hb.4 More  recently, Chintagari et al., in an in vitro study
and in mice with sickle cell disease (SCD), showed that Hp
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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Figure 1 – The Hp–Hb complex is cleared by the CD163 receptors expressed on the surface of macrophages and digested in
lysosomes to release heme. The Hp2-2 protein removes iron from circulation more  slowly because it is a larger molecule.
Consequently, in individuals with this phenotype, free Hb remains in the circulation longer and causes greater oxidative
stress. On the other hand, the Hp1-1 phenotype may be advantageous because the Hp1-1:Hb complex is removed to the
extravascular space more  rapidly than the other Hp complexes.attenuates the expression of heme oxygenase-1 (HO-1), an
important antioxidant and anti-inﬂammatory protein that,
stimulated by plasma free Hb, mediates the degradation of
heme to biliverdin, iron, and carbon monoxide.14 These results
suggest that treatment with Hp can reduce the toxicity of
free Hb after hemolysis.9 Preclinical studies are being carried
out with a view to evaluate how Hp could be used as a spe-
ciﬁc modulator in SCD and investigate possible adverse effects
of its use. A better understanding of this mechanism could
provide more  knowledge to exploit the therapeutic potential
of Hp to neutralize free Hb/heme in hemolytic anemias.4,5
In this volume of the Revista Brasileira de Hematologia e
Hemoterapia, Pierrot-Gallo et al.15 analyze the possible inﬂu-
ence of Hp genotypes on the secretion of IL-6 and IL-8 in 60
patients with stable SCA (aged 15–50 years old, 53% males;
recruited in the Hereditary Anemia Outpatient Clinic of the
Hematology and Blood Transfusion Unit, Universidade Fed-
eral de São Paulo – UNIFESP, Brazil). A group of 74 apparently
healthy individuals (aged 17–60 years old, 53% males; from
the same Brazilian region) was used as a control. In the study,
SCA patients were found to have signiﬁcantly higher levels
of IL-6 and IL-8 than controls, corroborating other studies.
However, no associations between Hp genotypes and these
cytokines were identiﬁed. Furthermore, an investigation ofthe prevalence of Hp genotypes did not reveal any signiﬁcant
differences.
This difﬁculty in evaluating a candidate phenotype modu-
lator (the Hp polymorphism) in a multifactorial disease such
as SCA can be seen from the authors’ comments on the lack
of agreement between the results for the distribution of the
Hp genotypes in studies of this kind. The Hp2-2 genotype
was found to be less represented in SCD patients in Nige-
ria (n = 54)16 and in SCA patients in the northeast of Brazil
(n = 599).17 On the other hand, the Hp1-1 genotype was less
represented in SCD patients from Kuwait (n = 82)16 and in SCA
patients from the southeast of Brazil (n = 60).15 This disagree-
ment may reﬂect the genetic background of the patients as
well as the inﬂuence of environmental factors and, especially,
the sample size, characteristics and quality in each study. The
representativeness of the number of patients analyzed, the
homogeneity of the criteria used to select patients, the pres-
ence of pediatric or adult patients in the sample and the extent
to which the control groups are formed and numerically equal
to or greater than the patient groups are some of the factors
that can cause heterogeneity when making this type of com-
parison. Furthermore, in multifactorial diseases the effects
of multiple genes and numerous environmental factors are
expected to be additive and to be associated with each other,
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eading to a multiplicity of effects that quite often makes it
irtually impossible to analyze each factor in isolation.
The results reported by Pierrot-Gallo et al.15 do not sup-
ort a conclusion that the Hp genotypes can modulate the
nﬂammatory response in the patients they studied. Neverthe-
ess, the possibility that Hp polymorphisms may contribute to
he clinical diversity observed in this condition, in combina-
ion with other genetic and environmental factors, should not
e excluded. Studies of the inﬂammatory components using
ore  representative sample sizes together with experimen-
al analyses could help to elucidate important aspects of the
linical behavior and survival of SCA patients.
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